Pharma Adapts Ovarian Cancer Drugs Amid Genomics Revolution
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Astra Zeneca hustles on genomic analyses of PARP inhibitor olaparib after drug fails to improve overall survival in a Phase II ovarian cancre trial, which could signify a revival. Meanwhile, Avastin lead investigator defends anti-angiogenesis approach, considering tremendous diversity of the relatively uncommon disease.